Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction
- PMID: 20233617
- DOI: 10.1016/j.atherosclerosis.2010.02.024
Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction
Abstract
Background: This study was designed to evaluate the potential role of metalloproteinase 2 (MMP2) in promoting the cleavage of TNF-related apoptosis inducing ligand (TRAIL), whose circulating levels are decreased after acute myocardial infarction (AMI).
Methods: The levels of MMP2 and of tissue inhibitor of metalloprotease 2 (TIMP2), as well as of TRAIL, were measured by ELISA in the serum of AMI patients and in the culture supernatant of endothelial cells.
Results: In AMI patients the serum levels of TRAIL showed a significant inverse correlation with the MMP2/TIMP2 ratio. In vitro MMP2 induced the cleavage of recombinant TRAIL and inactivated its ability of inducing apoptosis. Moreover, exposure of endothelial cells to TNF-alpha increased the MMP2/TIMP2 ratio in the culture supernatant.
Conclusions: An impaired MMP2/TIMP2 ratio might be involved in the decreased levels of circulating TRAIL observed after AMI.
Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction.Atherosclerosis. 2010 May;210(1):274-7. doi: 10.1016/j.atherosclerosis.2009.11.005. Epub 2009 Nov 10. Atherosclerosis. 2010. PMID: 20015493
-
Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases.Exp Cell Res. 2006 Nov 15;312(19):3892-8. doi: 10.1016/j.yexcr.2006.08.015. Epub 2006 Aug 25. Exp Cell Res. 2006. PMID: 16996498
-
Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1.Cancer Res. 2005 Feb 1;65(3):898-906. Cancer Res. 2005. PMID: 15705888
-
Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.Cancer Res. 2002 Jun 1;62(11):3093-9. Cancer Res. 2002. PMID: 12036919
-
Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients.Eur J Haematol. 2007 May;78(5):389-98. doi: 10.1111/j.1600-0609.2007.00834.x. Eur J Haematol. 2007. PMID: 17432976
Cited by
-
TRAIL and Cardiovascular Disease-A Risk Factor or Risk Marker: A Systematic Review.J Clin Med. 2021 Mar 18;10(6):1252. doi: 10.3390/jcm10061252. J Clin Med. 2021. PMID: 33803523 Free PMC article. Review.
-
Circulating TRAIL shows a significant post-partum decline associated to stressful conditions.PLoS One. 2011;6(12):e27011. doi: 10.1371/journal.pone.0027011. Epub 2011 Dec 14. PLoS One. 2011. PMID: 22194780 Free PMC article.
-
Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy.Cancers (Basel). 2019 Mar 29;11(4):444. doi: 10.3390/cancers11040444. Cancers (Basel). 2019. PMID: 30934872 Free PMC article. Review.
-
TRAIL signals, extracellular matrix and vessel remodelling.Vasc Biol. 2020 Jun 15;2(1):R73-R84. doi: 10.1530/VB-20-0005. eCollection 2020. Vasc Biol. 2020. PMID: 32923976 Free PMC article. Review.
-
TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?Clin Sci (Lond). 2019 May 16;133(10):1145-1166. doi: 10.1042/CS20181116. Print 2019 May 31. Clin Sci (Lond). 2019. PMID: 31097613 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
